Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo

Journal of Photochemistry and Photobiology B: Biology

Volumn 96, Issue 2, 2009, Pages 101-108

  Thomas, Noémie ^a   Bechet, Denise ^a   Becuwe, Philippe ^b   Tirand, Loraine ^a   Vanderesse, Régis ^c,d   Frochot, Céline ^b,d   Guillemin, François ^a,d   Barberi Heyob, Muriel ^a,d  

^a CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c LAB DE CHIM PHYS MACROMOLECULAIRE   (France)

^d GDR CNRS 3049 Médicaments Photoactivables Photochimiothé rapie PHOTOMED   (France)

Author keywords

Glioma bearing nude mice; Neuropilin 1; Peptide; siRNA; Targeted phototherapy; Vascular effect

Indexed keywords

5 (4 CARBOXYPHENYL) 10,15,20 TRIPHENYLCHLORIN; AMINOCAPROIC ACID; CHLORINE DERIVATIVE; HEPTAPEPTIDE; NEUROPILIN 1; NEUROPILIN 1 RECEPTOR; PEPTIDE DERIVATIVE; PHOTOSENSITIZING AGENT; RECEPTOR PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN BINDING; RNA INTERFERENCE; TUMOR BLOOD FLOW; TUMOR XENOGRAFT; UMBILICAL VEIN;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE SILENCING; HUMANS; MICE; NEUROPILIN-1; PEPTIDES; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROTEIN BINDING; RECOMBINANT PROTEINS;

MUS; MUS MUSCULUS;

EID: 67649982909     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2009.04.008     Document Type: Article

References (27)

1. Tozer G.M., and Bicknell R. Therapeutic targeting of the tumor vasculature. Semin. Radiat. Oncol. 14 3 (2004) 222-232
2. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer. 5 6 (2005) 423-435
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 1 (1995) 27-31
4. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., and Peng Q. Photodynamic therapy. J. Natl. Cancer I. 90 12 (1998) 889-905
5. Weersink R.A., Bogaards A., Gertner M., Davidson S.R., Zhang K., Netchev G., Trachtenberg J., and Wilson B.C. Techniques for delivery, monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate clinical experience and practicalities. J. Photochem. Photobiol. B 79 3 (2005) 211-222
6. Brekken R.A., Li C., and Kumar S. Strategies for vascular targeting in tumors. Int. J. Cancer 100 2 (2002) 123-130
7. Tirand L., Frochot C., Vanderesse R., Thomas N., Trinquet E., Pinel S., Viriot M.L., Guillemin F., and Barberi-Heyob M. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J. Control. Release 111 1-2 (2006) 153-164
8. Tirand L., Thomas N., Dodeller M., Dumas D., Frochot C., Maunit B., Guillemin F., and Barberi-Heyob M. Metabolic profile of a Peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study. Drug Metab. Dispos. 35 5 (2007) 806-813
9. Thomas N., Tirand L., Chatelut E., Plenat F., Frochot C., Dodeller M., Guillemin F., and Barberi-Heyob M. Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice. Photochem. Photobiol. Sci. 7 4 (2008) 433-441
10. Wilson B.C., and Patterson M.S. The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 53 9 (2008) 61-109
11. L. Tirand, T. Bastogne, D. Bechet, M. Linder, N. Thomas, C. Frochot, F. Guillemin, M. Barberi-Heyob, Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions, Int. J. Radiat. Oncol. Biol. Phys. (2009), doi:10.1016/j.ijrobp.2009.04.004.
12. Kattan Z., Marchal S., Brunner E., Ramacci C., Leroux A., Merlin J.L., Domenjoud L., Dauca M., and Becuwe P. Damaged DNA binding protein 2 plays a role in breast cancer cell growth. PLoS ONE 3 4 (2008) e2002
13. Bachelder R.E., Lipscomb E.A., Lin X., Wendt M.A., Chadborn N.H., Eickholt B.J., and Mercurio A.M. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res. 63 17 (2003) 5230-5233
14. Bianchi A., Becuwe P., Franck P., and Dauca M. Induction of MnSOD gene by arachidonic acid is mediated by reactive oxygen species and p38 MAPK signaling pathway in human HepG2 hepatoma cells. Free Radical Biol. Med. 32 11 (2002) 1132-1142
15. Pinel S., Barberi-Heyob M., Cohen-Jonathan E., Merlin J.L., Delmas C., Plenat F., and Chastagner P. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int. J. Radiat. Oncol. Biol. Phys. 59 1 (2004) 250-259
16. Kelleher D.K., Thews O., Scherz A., Salomon Y., and Vaupel P. Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide. Int. J. Oncol. 24 6 (2004) 1505-1511
17. Yu G., Durduran T., Zhou C., Wang H.W., Putt M.E., Saunders H.M., Sehgal C.M., Glatstein E., Yodh A.G., and Busch T.M. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin. Cancer Res. 11 9 (2005) 3543-3552
18. Starzec A., Vassy R., Martin A., Lecouvey M., Di Benedetto M., Crepin M., and Perret G.Y. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci. 79 25 (2006) 2370-2381
19. Perret G.Y., Starzec A., Hauet N., Vergote J., Le Pecheur M., Vassy R., Leger G., Verbeke K.A., Bormans G., Nicolas P., Verbruggen A.M., and Moretti J.L. In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1. Nucl. Med. Biol. 31 5 (2004) 575-581
20. Binetruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouet J., Derbin C., Perret G., and Mazie J.C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J. 19 7 (2000) 1525-1533
21. Ichikawa K., Hikita T., Maeda N., Yonezawa S., Takeuchi Y., Asai T., Namba Y., and Oku N. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta 1669 1 (2005) 69-74
22. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S., and Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 60 15 (2000) 4066-4069
23. Fingar V.H., Wieman T.J., Wiehle S.A., and Cerrito P.B. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 52 18 (1992) 4914-4921
24. Garbo G.M., Vicente M.G., Fingar V., and Kessel D. Effects of ursodeoxycholic acid on photodynamic therapy in a murine tumor model. Photochem. Photobiol. 78 4 (2003) 407-410
25. Pogue B.W., Braun R.D., Lanzen J.L., Erickson C., and Dewhirst M.W. Analysis of the heterogeneity of pO2 dynamics during photodynamic therapy with verteporfin. Photochem. Photobiol. 74 5 (2001) 700-706
26. Chen Z., Milner T.E., Wang X., Srinivas S., and Nelson J.S. Optical Doppler tomography: imaging in vivo blood flow dynamics following pharmacological intervention and photodynamic therapy. Photochem. Photobiol. 67 1 (1998) 56-60
27. Leach R.M., Hill H.S., Snetkov V.A., and Ward J.P. Hypoxia, energy state and pulmonary vasomotor tone. Resp. Physiol. Neurobiol. 132 1 (2002) 55-67